328 related articles for article (PubMed ID: 31077910)
1. Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents.
Elsaman T; Mohamed MS; Mohamed MA
Bioorg Chem; 2019 Jul; 88():102969. PubMed ID: 31077910
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of nitrofuranyl methyl N-heterocycles derivatives as novel antitubercular agents.
Wang A; Li W; Wang B; Lv K; Wang H; Liu M; Guo H; Lu Y
Future Med Chem; 2018 Sep; 10(17):2059-2068. PubMed ID: 29992836
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of nitrofuran-1,3,4-oxadiazole hybrids as new antitubercular agents.
Wang A; Xu S; Chai Y; Xia G; Wang B; Lv K; Wang D; Qin X; Jiang B; Wu W; Liu M; Lu Y
Bioorg Med Chem; 2022 Jan; 53():116529. PubMed ID: 34861474
[TBL] [Abstract][Full Text] [Related]
4. Conjugation of a 5-nitrofuran-2-oyl moiety to aminoalkylimidazoles produces non-toxic nitrofurans that are efficacious in vitro and in vivo against multidrug-resistant Mycobacterium tuberculosis.
Krasavin M; Lukin A; Vedekhina T; Manicheva O; Dogonadze M; Vinogradova T; Zabolotnykh N; Rogacheva E; Kraeva L; Yablonsky P
Eur J Med Chem; 2018 Sep; 157():1115-1126. PubMed ID: 30179748
[TBL] [Abstract][Full Text] [Related]
5. Current Advances in Antitubercular Drug Discovery: Potent Prototypes and New Targets.
Dos Santos Fernandes GF; Jornada DH; de Souza PC; Chin CM; Pavan FR; Dos Santos JL
Curr Med Chem; 2015; 22(27):3133-61. PubMed ID: 26282941
[TBL] [Abstract][Full Text] [Related]
6. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
7. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
8. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
9. Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains.
Onajole OK; Pieroni M; Tipparaju SK; Lun S; Stec J; Chen G; Gunosewoyo H; Guo H; Ammerman NC; Bishai WR; Kozikowski AP
J Med Chem; 2013 May; 56(10):4093-103. PubMed ID: 23611124
[TBL] [Abstract][Full Text] [Related]
10. Recent developments of coumarin-containing derivatives and their anti-tubercular activity.
Hu YQ; Xu Z; Zhang S; Wu X; Ding JW; Lv ZS; Feng LS
Eur J Med Chem; 2017 Aug; 136():122-130. PubMed ID: 28494250
[TBL] [Abstract][Full Text] [Related]
11. Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agent.
Gallardo-Macias R; Kumar P; Jaskowski M; Richmann T; Shrestha R; Russo R; Singleton E; Zimmerman MD; Ho HP; Dartois V; Connell N; Alland D; Freundlich JS
Bioorg Med Chem Lett; 2019 Feb; 29(4):601-606. PubMed ID: 30600207
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
13. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.
Centers for Disease Control and Prevention (CDC)
MMWR Recomm Rep; 2009 Feb; 58(RR-3):1-43. PubMed ID: 19214162
[TBL] [Abstract][Full Text] [Related]
14. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
15. Isoniazid derivatives and their anti-tubercular activity.
Hu YQ; Zhang S; Zhao F; Gao C; Feng LS; Lv ZS; Xu Z; Wu X
Eur J Med Chem; 2017 Jun; 133():255-267. PubMed ID: 28390957
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents.
Ran K; Gao C; Deng H; Lei Q; You X; Wang N; Shi Y; Liu Z; Wei W; Peng C; Xiong L; Xiao K; Yu L
Bioorg Med Chem Lett; 2016 Aug; 26(15):3669-74. PubMed ID: 27289321
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the research of heterocyclic compounds as antitubercular agents.
Yan M; Ma S
ChemMedChem; 2012 Dec; 7(12):2063-75. PubMed ID: 23042656
[TBL] [Abstract][Full Text] [Related]
18. Attachment of a 5-nitrofuroyl moiety to spirocyclic piperidines produces non-toxic nitrofurans that are efficacious in vitro against multidrug-resistant Mycobacterium tuberculosis.
Krasavin M; Lukin A; Vedekhina T; Manicheva O; Dogonadze M; Vinogradova T; Zabolotnykh N; Rogacheva E; Kraeva L; Sharoyko V; Tennikova TB; Dar'in D; Sokolovich E
Eur J Med Chem; 2019 Mar; 166():125-135. PubMed ID: 30703656
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis and its Treatment: An Overview.
Bansal R; Sharma D; Singh R
Mini Rev Med Chem; 2018; 18(1):58-71. PubMed ID: 27553018
[TBL] [Abstract][Full Text] [Related]
20. Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB.
Pieroni M; Tipparaju SK; Lun S; Song Y; Sturm AW; Bishai WR; Kozikowski AP
ChemMedChem; 2011 Feb; 6(2):334-42. PubMed ID: 21259445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
